CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-16 | Mehta Vimal CEO and President | Sale 10b5-1 | −2,134 | $0.36 | $773 | 59,605 |
| 2024-12-16 | Steinhart Richard I Chief Financial Officer | Sale 10b5-1 | −205 | $0.36 | $74 | 21,157 |
| 2024-12-16 | Steinhart Richard I Chief Financial Officer | Sale 10b5-1 | −372 | $0.36 | $133 | 20,932 |
| 2024-12-16 | Rodriguez Javier See Remarks | Sale 10b5-1 | −210 | $0.36 | $75 | 24,643 |
| 2024-12-16 | Rodriguez Javier See Remarks | Sale 10b5-1 | −220 | $0.36 | $78 | 24,423 |
| 2024-12-16 | Yocca Frank Chief Scientific Officer | Sale 10b5-1 | −205 | $0.36 | $73 | 29,156 |
| 2024-12-16 | Yocca Frank Chief Scientific Officer | Sale 10b5-1 | −225 | $0.35 | $79 | 28,931 |
| 2024-12-15 | Mehta Vimal CEO and President | Option exercise 10b5-1 | +3,500 | 61,903 | ||
| 2024-12-15 | Mehta Vimal CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −3,500 | 31,500 | ||
| 2024-12-15 | Steinhart Richard I Chief Financial Officer | Option exercise 10b5-1 | +562 | 21,362 | ||
| 2024-12-15 | Steinhart Richard I Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −562 | 5,064 | ||
| 2024-12-15 | Rodriguez Javier See Remarks | Option exercise 10b5-1 | +562 | 24,853 | ||
| 2024-12-15 | Rodriguez Javier See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −562 | 5,064 | ||
| 2024-12-15 | Yocca Frank Chief Scientific Officer | Option exercise 10b5-1 | +562 | 29,361 | ||
| 2024-12-15 | Yocca Frank Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −562 | 5,064 | ||
| 2024-12-14 | O'Neill Vincent See Remarks | Option exercise 10b5-1 | +521 | 20,122 | ||
| 2024-12-14 | O'Neill Vincent See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −521 | 2,606 | ||
| 2024-12-14 | Mehta Vimal CEO and President | Option exercise 10b5-1 | +2,610 | 58,403 | ||
| 2024-12-14 | Mehta Vimal CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −2,610 | 13,049 | ||
| 2024-12-14 | Steinhart Richard I Chief Financial Officer | Option exercise 10b5-1 | +521 | 20,800 |
Page 9 of 27 · 521 trades